Cannabinoid derivatives acting as dual PPARγCB2 agonists as therapeutic agents for systemic sclerosis.
The endocannabinoid system (ECS) may play a role in the pathophysiology of systemic sclerosis (SSc). Cannabinoids acting as dual PPARγCB